Skip to content
OpenCapital
Get started

Spyre Therapeutics, Inc. SYRE Gain in connection with sale

Other financials

Income statement

See full
Revenue-—
Operating income-$45.6M+14.8%
Net income-$69.0M-54.1%
EPS (diluted)-$0.74-23.3%

Balance sheet

See full
Cash & equivalents$97.2M+100%
Total debt$4.3M-9.6%
Total equity$670.8M+39.0%
Total assets$764.0M+34.1%

Cash flow

See full
Operating cash flow-$57.4M-40.0%
CapEx-—
Free cash flow-$39.4M-26.8%

Valuation

See full
Market cap$7.67B+307%

Profitability

See full
Operating margin-39,428.9%-49,795pp
Net margin-52,939.7%-61,871pp
FCF margin-3,442.8%-3,807pp

Returns & leverage

See full
Return on equity-31.1%-10.7pp
Debt / equity0.1×+0.1×
Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s gain in connection with sale.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s gain in connection with sale?
Spyre Therapeutics, Inc. (SYRE) reported gain in connection with sale of $30M in Q1 2026.